UNLABELLED: Mice deficient in small heterodimer partner (SHP) are protected from diet-induced hepatic steatosis resulting from increased fatty acid oxidation and decreased lipogenesis. The decreased lipogenesis appears to be a direct consequence of very low expression of peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2), a potent lipogenic transcription factor, in the SHP(-/-) liver. The current study focused on the identification of a SHP-dependent regulatory cascade that controls PPAR-γ2 gene expression, thereby regulating hepatic fat accumulation. Illumina BeadChip array (Illumina, Inc., San Diego, CA) and real-time polymerase chain reaction were used to identify genes responsible for the linkage between SHP and PPAR-γ2 using hepatic RNAs isolated from SHP(-/-) and SHP-overexpressing mice. The initial efforts identify that hairy and enhancer of split 6 (Hes6), a novel transcriptional repressor, is an important mediator of the regulation of PPAR-γ2 transcription by SHP. The Hes6 promoter is specifically activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-trans retinoic acid (atRA), and is repressed by SHP. Hes6 subsequently represses hepatocyte nuclear factor 4 alpha (HNF-4α)-activated PPAR-γ2 gene expression by direct inhibition of HNF-4α transcriptional activity. Furthermore, we provide evidences that atRA treatment or adenovirus-mediated RAR-α overexpression significantly reduced hepatic fat accumulation in obese mouse models, as observed in earlier studies, and the beneficial effect is achieved by the proposed transcriptional cascade. CONCLUSIONS: Our study describes a novel transcriptional regulatory cascade controlling hepatic lipid metabolism that identifies retinoic acid signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.
UNLABELLED: Mice deficient in small heterodimer partner (SHP) are protected from diet-induced hepatic steatosis resulting from increased fatty acid oxidation and decreased lipogenesis. The decreased lipogenesis appears to be a direct consequence of very low expression of peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2), a potent lipogenic transcription factor, in the SHP(-/-) liver. The current study focused on the identification of a SHP-dependent regulatory cascade that controls PPAR-γ2 gene expression, thereby regulating hepatic fat accumulation. Illumina BeadChip array (Illumina, Inc., San Diego, CA) and real-time polymerase chain reaction were used to identify genes responsible for the linkage between SHP and PPAR-γ2 using hepatic RNAs isolated from SHP(-/-) and SHP-overexpressing mice. The initial efforts identify that hairy and enhancer of split 6 (Hes6), a novel transcriptional repressor, is an important mediator of the regulation of PPAR-γ2 transcription by SHP. The Hes6 promoter is specifically activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-trans retinoic acid (atRA), and is repressed by SHP. Hes6 subsequently represses hepatocyte nuclear factor 4 alpha (HNF-4α)-activated PPAR-γ2 gene expression by direct inhibition of HNF-4α transcriptional activity. Furthermore, we provide evidences that atRA treatment or adenovirus-mediated RAR-α overexpression significantly reduced hepatic fat accumulation in obesemouse models, as observed in earlier studies, and the beneficial effect is achieved by the proposed transcriptional cascade. CONCLUSIONS: Our study describes a novel transcriptional regulatory cascade controlling hepatic lipid metabolism that identifies retinoic acid signaling as a new therapeutic approach to nonalcoholic fatty liver diseases.
Authors: Li Wang; Jun Liu; Pradip Saha; Jiansheng Huang; Lawrence Chan; Bruce Spiegelman; David D Moore Journal: Cell Metab Date: 2005-10 Impact factor: 27.287
Authors: Chiao-Chien Connie Hung; I Sadaf Farooqi; Ken Ong; Jian'an Luan; Julia M Keogh; Marcus Pembrey; Giles S H Yeo; David Dunger; Nicholas J Wareham; Stephen O' Rahilly Journal: Diabetes Date: 2003-05 Impact factor: 9.461
Authors: Thaddeus T Schug; Daniel C Berry; Illia A Toshkov; Le Cheng; Alexander Yu Nikitin; Noa Noy Journal: Proc Natl Acad Sci U S A Date: 2008-05-21 Impact factor: 11.205
Authors: Florian W Kiefer; Cecile Vernochet; Patrick O'Brien; Steffen Spoerl; Jonathan D Brown; Shriram Nallamshetty; Maximilian Zeyda; Thomas M Stulnig; David E Cohen; C Ronald Kahn; Jorge Plutzky Journal: Nat Med Date: 2012-06 Impact factor: 53.440
Authors: Young Joo Park; Mohammed Qatanani; Steven S Chua; Jennifer L LaRey; Stacy A Johnson; Mitsuhiro Watanabe; David D Moore; Yoon Kwang Lee Journal: Hepatology Date: 2008-05 Impact factor: 17.425
Authors: Sasmita Tripathy; John D Chapman; Chang Y Han; Cathryn A Hogarth; Samuel L M Arnold; Jennifer Onken; Travis Kent; David R Goodlett; Nina Isoherranen Journal: Mol Pharmacol Date: 2016-02-26 Impact factor: 4.436
Authors: Sebastian C Hasenfuss; Latifa Bakiri; Martin K Thomsen; Evan G Williams; Johan Auwerx; Erwin F Wagner Journal: Cell Metab Date: 2014-01-07 Impact factor: 27.287
Authors: Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman Journal: Hepatology Date: 2019-03-05 Impact factor: 17.425